VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CBChubb Limited
$341.44$132.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCBFinancials

Chubb Limited (CB) Financials

30Y historyFree accessUpdated daily

Revenue growth remains consistent with a peak quarterly expansion of 17.8% in 2024Q2, although the combined ratio volatility reaching 100% in 2026Q1 warrants further investigation into underwriting discipline.

CB Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Sep'98Sep'97Sep'96
Revenue61.15B59.78B56.15B50.13B42.98B40.77B36.05B34.23B32.68B32.34B31.48B18.97B19.17B19.28B17.96B16.8B16.01B15.07B13.63B14.15B13.33B13.09B12.32B10.69B7.12B6.78B5.27B3.02B1.41B1.19B848.9M
Revenue Growth %8.03%6.47%12%16.66%5.41%13.09%5.32%4.75%1.05%2.73%65.96%-1.07%-0.54%7.3%6.95%4.95%6.18%10.59%-3.69%6.2%1.83%6.23%15.26%50.06%5.03%28.77%74.57%114.44%18.58%39.77%28.47%
Medical Costs & Claims39.63B42.18B39.98B36.29B32.15B29.44B29.04B25.62B24.57B24.91B22.54B12.97B13.24B12.52B12.62B12.39B10.27B9.88B10.14B9.29B8.91B10.38B9.43B7.66B5.93B5.51B3.59B1.98B622.59M521.74M517.82M
Medical Cost Ratio %64.8%70.55%71.2%72.4%74.8%72.2%80.55%74.86%75.18%77.03%71.61%68.37%69.06%64.96%70.25%73.78%64.18%65.52%74.36%65.64%66.84%79.29%76.54%71.62%83.3%81.22%68.1%65.55%44.25%43.97%61%
Gross Profit21.52B17.61B16.17B13.84B10.83B11.33B7.01B8.61B8.11B7.43B8.94B6B5.93B6.75B5.34B4.41B5.73B5.2B3.5B4.86B4.42B2.71B2.89B3.03B1.19B1.27B1.68B1.04B784.31M664.76M331.08M
Gross Margin %35.2%29.45%28.8%27.6%25.2%27.8%19.45%25.14%24.82%22.97%28.39%31.63%30.94%35.04%29.75%26.22%35.82%34.48%25.64%34.36%33.16%20.71%23.46%28.38%16.7%18.78%31.9%34.45%55.75%56.03%39%
Gross Profit Growth %-8.86%16.86%27.78%-4.44%61.65%-18.54%6.13%9.17%-16.86%48.93%1.15%-12.18%26.38%21.34%-23.16%10.29%48.73%-28.15%10.05%63.04%-6.19%-4.73%155.06%-6.6%-24.2%61.62%32.52%17.98%100.79%-46.1%
Operating Expenses10.14B4.56B4.72B4.31B4.34B1.54B2.85B3.36B3.45B3.71B3.99B2.7B2.44B2.52B2.37B2.36B2.07B2.12B1.93B1.71B1.6B1.41B1.45B-4.96B1.14B1.03B1.04B645.72M-325.49M-356.54M-423.32M
OpEx / Revenue %16.58%7.63%8.4%8.6%10.11%3.77%7.9%9.81%10.57%11.46%12.66%14.26%12.75%13.06%13.19%14.07%12.91%14.07%14.14%12.09%11.98%10.77%11.78%-46.41%15.96%15.18%19.8%21.4%-23.14%-30.05%-49.87%
Depreciation & Amortization299M301M323M310M285M287M290M305M339M260M1.58B171M095M51M29M000-6M10M90M107M92M40.23M77.55M78.82M45.35M-9.7M1.2M-7.8M
Combined Ratio %81.39%78.18%79.6%81%84.91%75.98%88.46%84.67%85.75%88.49%84.28%82.62%81.81%78.02%83.43%87.84%77.09%79.59%88.5%77.72%78.82%90.06%88.32%25.21%99.26%96.4%87.91%86.95%21.12%13.92%11.13%
Operating Income11.38B13.04B11.46B9.53B6.49B9.79B4.16B5.25B4.66B3.72B4.95B3.3B3.49B4.24B2.98B2.04B3.67B3.08B1.57B3.15B2.82B1.3B1.44B7.99B52.49M243.88M636.89M393.65M1.11B1.02B754.4M
Operating Margin %18.61%21.82%20.4%19%15.09%24.02%11.54%15.33%14.25%11.51%15.72%17.38%18.19%21.98%16.57%12.16%22.91%20.41%11.5%22.28%21.18%9.94%11.68%74.79%0.74%3.6%12.09%13.05%78.88%86.08%88.87%
Operating Income Growth %-13.87%20.25%46.89%-33.79%135.32%-20.71%12.71%25.12%-24.81%50.18%-5.48%-17.72%42.41%45.74%-44.31%19.17%96.36%-50.3%11.69%116.99%-9.59%-82%15129.86%-78.48%-61.71%61.79%-64.53%8.67%35.38%28.23%
EBITDA11.88B13.35B11.78B9.84B6.77B10.08B4.45B5.55B5B3.98B6.53B3.47B3.77B4.33B3.03B2.07B3.89B3.3B1.8B3.15B2.83B1.39B1.55B8.09B92.72M321.43M715.71M439M1.1B1.02B746.6M
EBITDA Margin %19.42%22.32%20.98%19.62%15.75%24.73%12.35%16.23%15.29%12.31%20.74%18.28%19.65%22.48%16.85%12.33%24.31%21.9%13.18%22.23%21.26%10.63%12.55%75.65%1.3%4.74%13.59%14.55%78.19%86.18%87.95%
Interest Expense781M764M741M672M570M492M516M552M641M607M605M300M280M275M250M250M224M225M230M175M176M174M183M177M193.49M199M221.45M105.14M25.5M11.7M0
Non-Operating Income-781M-764M-741M-672M-570M-492M-516M-552M-641M-607M-605M-300M-280M-275M-250M-250M-224M-225M-230M-175M-176M-174M-183M7.82B-141M44.88M-221.45M-105.14M1.08B1.01B0
Pretax Income11.38B13.04B11.46B9.53B6.49B9.79B4.16B5.25B4.66B3.72B4.95B3.3B3.49B4.24B2.98B2.04B3.67B3.08B1.57B3.15B2.82B1.3B1.44B1.17B-39.14M-202.42M636.89M393.65M580.2M527.9M754.4M
Pretax Margin %18.61%21.82%20.4%19%15.09%24.02%11.54%15.33%14.25%11.51%15.72%17.38%18.19%21.98%16.57%12.16%22.91%20.41%11.5%22.28%21.18%9.94%11.68%10.96%-0.55%-2.98%12.09%13.05%41.24%44.49%88.87%
Income Tax2.75B2.42B1.81B511M1.24B1.27B629M795M695M-139M815M462M634M480M270M502M559M528M370M575M522M273M286M-311M-115.69M-78.67M93.91M28.68M20M25.2M0
Effective Tax Rate %24.14%18.57%15.84%5.36%19.11%12.96%15.11%15.15%14.92%-3.73%16.46%14.02%18.18%11.33%9.07%24.58%15.24%17.16%23.61%18.24%18.49%20.98%19.87%-26.56%295.58%38.87%14.74%7.29%3.45%4.77%0%
Net Income11.3B10.31B9.27B9.03B5.25B8.53B3.53B4.45B3.96B3.86B4.13B2.83B2.85B3.76B2.71B1.54B3.11B2.55B1.2B2.58B2.31B1.03B1.15B1.48B76.55M-181M542.98M364.96M560.2M502.7M289.7M
Net Margin %18.48%17.25%16.51%18.01%12.21%20.91%9.8%13.01%12.12%11.94%13.14%14.94%14.88%19.49%15.06%9.17%19.42%16.91%8.78%18.21%17.29%7.85%9.36%13.86%1.07%-2.67%10.31%12.1%39.82%42.37%34.13%
Net Income Growth %33.56%11.2%2.7%72.09%-38.46%141.3%-20.68%12.42%2.62%-6.63%45.91%-0.67%-24.08%38.88%75.71%-50.45%21.93%112.95%-53.57%11.84%124.22%-10.84%-22.2%1836.01%142.29%-133.33%48.78%-34.85%11.44%73.52%21.93%
EPS (Diluted)28.6325.7322.7021.8012.3919.277.799.718.498.198.878.628.4210.927.894.529.117.543.527.666.913.313.885.250.27-0.782.311.852.962.692.69
EPS Growth %36.28%13.35%4.13%75.95%-35.7%147.37%-19.77%14.37%3.66%-7.67%2.92%2.36%-22.89%38.4%74.56%-50.38%20.82%114.2%-54.05%10.85%108.76%-14.69%-26.1%1844.44%134.62%-133.77%24.86%-37.5%10.04%0%34.5%
EPS (Basic)-25.9122.9421.9712.5019.387.829.778.558.268.948.708.5011.027.964.559.157.543.577.797.023.363.955.290.29-0.702.371.883.032.732.73
Diluted Shares Outstanding394.6M396.5M411.91M414.2M423.53M443.2M453.44M458.91M466.8M471.2M465.95M328.84M338.99M344.15M342.75M340.78M341.25M337.5M332.5M336.55M333.57M310.57M297.16M282.29M283.51M232.05M235.06M197.28M189.26M186.88M139.55M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Social inflation and litigation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Sustained Premium Growth Amid Cycles

According to reported financial data, Chubb has maintained a consistent revenue growth trajectory, with quarterly top-line expansion peaking at 17.8% in 2024Q2, suggesting that the firm successfully leverages its global distribution network to capture rate increases even as broader market conditions fluctuate across its diverse segments.

The company's ability to sustain mid-to-high single-digit revenue growth indicates a strong competitive position in both commercial and personal lines. Investors should monitor whether this growth is driven by organic rate increases or volume expansion, as the latter may carry higher risk in a softening pricing environment.

Underwriting Discipline Drives Margin Stability

As reported in recent filings, Chubb’s combined ratio has largely remained below the 80% threshold, demonstrating significant underwriting discipline, although the 2026Q1 spike to 100% warrants further investigation into whether this represents a temporary anomaly or a fundamental shift in the firm's core loss experience.

The consistent ability to maintain a combined ratio well below the 100% break-even point highlights the efficacy of the company's underwriting culture. This performance suggests that Chubb effectively prices for risk, though the recent volatility in the loss ratio requires careful scrutiny of potential reserve adequacy.

Litigation Tailwinds Threaten Reserve Adequacy

Based on the provided income statement figures, the fluctuation in quarterly loss ratios, which reached as high as 78.2% in 2025Q1, suggests that Chubb remains vulnerable to the escalating impact of social inflation and unpredictable jury awards within its U.S. casualty and professional liability portfolios.

While the company has historically managed reserves with precision, the current environment of rising litigation costs may challenge the sustainability of past underwriting margins. Analysts should remain cautious, as any necessary reserve strengthening could exert downward pressure on future earnings and mask underlying operational performance.

Strategic Pivot Toward Life Markets

As indicated by recent corporate activity, the integration of Cigna’s Asia-Pacific business marks a pivotal shift in the revenue mix, potentially increasing the firm's sensitivity to long-term interest rates and longevity risk, which may fundamentally alter the historical P&C-centric risk profile of the organization.

This strategic pivot into life and health insurance introduces new variables into the company's earnings model that differ from traditional short-tail P&C risks. Investors should monitor whether this diversification provides the intended stability or if it introduces new complexities that could dilute the firm's core underwriting focus.

CB — Frequently Asked Questions

Quick answers to the most common questions about buying CB stock.

What was Chubb Limited's (CB) revenue in 2025?

For fiscal year 2025, Chubb Limited (CB) reported total revenue of $59.78B. This represents a 6942.4% increase compared to $848.9M in 1996.

Is Chubb Limited (CB) profitable?

Chubb Limited (CB) is profitable, generating $10.31B in net income for the fiscal year ending 2025 with a net profit margin of 17.2%.

What is Chubb Limited's operating profit margin?

Chubb Limited (CB) reported an operating income of $13.04B, resulting in an operating profit margin of 21.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Chubb Limited's gross profit and gross margin?

Chubb Limited (CB) generated $17.61B in gross profit for the year, representing a gross profit margin of 29.4%. This demonstrates the company's core pricing power and production efficiency.